Sarepta Therapeutics (Commercial Rights to DMD Drug) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Sarepta Therapeutics (Commercial Rights to DMD Drug) General Information

Description

Rights to a drug for treating duchenne muscular dystrophy.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Drug Delivery
Pharmaceuticals
Acquirer
Corporate Office
  • 215 First Street
  • Cambridge, MA 02142
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sarepta Therapeutics (Commercial Rights to DMD Drug) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sarepta Therapeutics (Commercial Rights to DMD Drug)‘s full profile, request access.

Request a free trial

Sarepta Therapeutics (Commercial Rights to DMD Drug) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sarepta Therapeutics (Commercial Rights to DMD Drug)‘s full profile, request access.

Request a free trial

Sarepta Therapeutics (Commercial Rights to DMD Drug) FAQs

  • Where is Sarepta Therapeutics (Commercial Rights to DMD Drug) headquartered?

    Sarepta Therapeutics (Commercial Rights to DMD Drug) is headquartered in Cambridge, MA.

  • What industry is Sarepta Therapeutics (Commercial Rights to DMD Drug) in?

    Sarepta Therapeutics (Commercial Rights to DMD Drug)’s primary industry is Buildings and Property.

  • Is Sarepta Therapeutics (Commercial Rights to DMD Drug) a private or public company?

    Sarepta Therapeutics (Commercial Rights to DMD Drug) is a Private company.

  • What is the current valuation of Sarepta Therapeutics (Commercial Rights to DMD Drug)?

    The current valuation of Sarepta Therapeutics (Commercial Rights to DMD Drug) is 00.000.

  • What is Sarepta Therapeutics (Commercial Rights to DMD Drug)’s current revenue?

    The current revenue for Sarepta Therapeutics (Commercial Rights to DMD Drug) is 000000.

  • Who are Sarepta Therapeutics (Commercial Rights to DMD Drug)’s investors?

    Sarepta Therapeutics has invested in Sarepta Therapeutics (Commercial Rights to DMD Drug).

  • When was Sarepta Therapeutics (Commercial Rights to DMD Drug) acquired?

    Sarepta Therapeutics (Commercial Rights to DMD Drug) was acquired on 23-Dec-2019.

  • Who acquired Sarepta Therapeutics (Commercial Rights to DMD Drug)?

    Sarepta Therapeutics (Commercial Rights to DMD Drug) was acquired by Roche.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »